Related Experiment Video

Updated: Mar 15, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.7K

Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy

Ting Hu1, Rui Zhou1, Yanxia Zhao1

  • 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan 430022, China.

Scientific Reports
|September 15, 2016
PubMed

Insights

Integrin α6 (ITGA6) is upregulated in breast cancer, promoting radiation resistance by influencing apoptosis, DNA repair, and cell cycle regulation via PI3K/Akt and MEK/Erk pathways. Targeting ITGA6 may enhance radiotherapy effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Integrin α6 (ITGA6) is a cell adhesion receptor protein.
  • ITGA6 is frequently overexpressed in various cancers, correlating with increased migration and invasion.
  • The specific role of ITGA6 in breast cancer radiosensitivity remains largely uncharacterized.

Purpose of the Study:

  • To investigate the expression of ITGA6 in breast cancer.
  • To elucidate the function of ITGA6 in regulating radiation sensitivity in breast cancer cells.
  • To identify the signaling pathways involved in ITGA6-mediated radioresistance.

Main Methods:

  • Western blot analysis to assess ITGA6 protein and mRNA expression.
  • Colony formation assays to evaluate cell survival post-irradiation.
  • Cell cycle analysis, apoptosis assays, and immunofluorescence to study cellular responses to radiation.
  • Pharmacological inhibition of PI3K/Akt and MEK/Erk pathways.

Main Results:

  • ITGA6 expression was significantly higher in breast cancer cells compared to normal breast cells.
  • ITGA6 overexpression conferred resistance to radiotherapy by modulating apoptosis, DNA damage repair, and cell cycle progression.
  • ITGA6 mediated radioresistance through activation of the PI3K/Akt and MEK/Erk signaling pathways.
  • Inhibition of PI3K (using LY294002) and MEK (using U0126) pathways abrogated the radiation-resistant phenotype induced by ITGA6 overexpression.

Conclusions:

  • ITGA6 plays a crucial role in promoting radioresistance in breast cancer.
  • ITGA6 influences key cellular processes including apoptosis, DNA repair, and cell cycle regulation in response to radiation.
  • The PI3K/Akt and MEK/Erk signaling cascades are integral to ITGA6-mediated radioresistance.
  • ITGA6 represents a potential therapeutic target for overcoming radiation resistance in breast cancer treatment.

More Related Videos

Three-Dimensional 3D Tumor Spheroid Invasion Assay12:19

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

59.9K
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

5.2K

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
5.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K